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Background and Purpose: N-methyl-D-aspartate (NMDA)-mediated neurotoxicity and oxidative stress have been 
implicated in the etiology of amyotrophic lateral sclerosis (ALS). Memantine is a low-affinity, noncompetitive NMDA 
receptor antagonist that may protect against motor neuron degeneration.
Methods: Thirty transgenic mice expressing the G93A SOD1 mutation were randomly divided into control, low- 
dose memantine (30 mg/kg/day), and high-dose memantine (90 mg/kg/day) groups, with memantine supplied daily 
with drinking water beginning at 75 days of age. Body weight, survival, and behavioral performances including a 
rotarod test, paw grip endurance, and hindlimb extension reflex were assessed in the control and memantine-diet 
groups.
Results: Clinical symptoms were evident in the G93A transgenic mice by 11 weeks of age. Memantine was 
tolerated well. Compared to control, mice treated with memantine performed better in the rotarod test and hindlimb 
extension reflex. Moreover, low-dose memantine treatment significantly prolonged the survival of the transgenic 
mice relative to control mice (141 vs 134 days, p<0.05).
Conclusion: These findings suggest that memantine, even when administered at the time of symptom onset, has 
beneficial effects on patients with ALS.
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INTRODUCTION
Glutamate is a major excitatory neurotransmitter in 
the central nervous system, and excessive activation 
of glutamate receptors can damage neurons via 
excitotoxicity. There are several lines of evidence 
that excitotoxicity plays a role in selective motor 
neuron death in amyotrophic lateral sclerosis (ALS).
1-3 
Elevation of the extracellular glutamate level causes 
degeneration of motor neurons through excessive 
stimulation of glutamate receptors. Both N-methyl-D- 
aspartate (NMDA) and α-amino-3-hydroxy-5-methyl- 
4-isoxazole propionic acid (AMPA) receptors are 
responsible for excitotoxicity in motor neurons.
4,5 
This has led to several antiglutamate drugs being 
tested on patients with ALS,
6 of which riluzole has 
a modest effect on survival and is the only such drug Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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approved by the US Food and Drug Adminstration 
for ALS.
7,8
Riluzole inhibits glutamate release by inactivating 
voltage-dependent sodium channels and a G-protein- 
dependent signal transduction process at glutama-
tergic nerve terminals.
9 Because NMDA receptors 
play crucial roles in various forms of synaptic 
plasticity, which is required in several normal pro-
cesses such as learning and memory,
10,11 drugs such 
as riluzole that completely block NMDA receptors 
would inevitably impair normal synaptic transmission 
and thereby cause numerous unwanted side effects. 
Such side effects could be avoided by producing a 
partial rather than a complete blockade of NMDA 
receptors.
Memantine is a low-affinity, noncompetitive open- 
channel receptor blocker with a rapid off-rate from 
the channel, permitting the blockade of excessive 
NMDA receptor activity without disrupting normal 
synaptic transmission.
12,13 Neuroprotective properties 
of memantine have been shown in various in vitro 
and  in vivo models of excitotoxicity,
14,15 and it has 
been used clinically with excellent safety in various 
neurodegenerative disorders including Alzheimer’s 
disease.
16,17 In a recent study, memantine significantly 
delayed disease progress and increased the life span 
by about 1 week in a transgenic ALS mouse model 
carrying the G93A mutant of the human Cu-Zn 
superoxide dismutase (SOD) gene,
18 with immuno-
histochemistry revealing the expression of NMDA 
receptor subunits within neurons of varying sizes in 
both dorsal and ventral areas of the spinal cord, 
including motor neurons.
18 However, the starting 
point and delivery method of memantine treatment 
employed in that study are unfortunately not readily 
applicable in clinical treatments of patients with 
ALS.
In the present study, we attempted to determine 
the effect of oral administration of memantine given 
at the time of symptom onset on behaviors and 
survival of transgenic SOD1 mutant ALS mice.
MATERIALS AND METHODS
1. Animals and memantine treatment
Transgenic mice overexpressing human SOD1 
with a Gly-to-Ala mutation at position 93 were pur-
chased from Jackson Laboratory (Bar Harbor, ME, 
USA) and maintained as hemizygotes by breeding 
transgenic males with wild-type B6SJL females. The 
transgenic progeny were genotyped for expression of 
the transgene by the polymerase chain reaction using 
primers specific for human SOD1. Throughout the 
experiments, animals were housed in a controlled 
environment (temperature of 20–22℃, humidity of 
40–60%, and lights on from 0700 to 1900 hours) 
with free access to food and water. The animals 
were randomly divided into control, low-dose me-
mantine (30 mg/kg/day), and high-dose memantine 
(90 mg/kg/day) groups, with 10 animals in each group. 
The transgenic mice were treated daily with memantine 
in the drinking water, beginning at 75 days of age. 
The daily dosage was calculated based on a daily 
water intake of 17.7 ml/100g/day.
19 Fresh solutions 
were prepared weekly.
2. Behavioral analysis
Motor performance was evaluated twice weekly by 
a rotarod test (Columbus Instruments, OH, USA), 
paw grip endurance (PaGE), and an extension reflex 
of hindlimbs, beginning at 10 weeks of age after a 
2-week learning period. The time period that mice 
remained on a rotarod rotating at a constant speed of 
16 rpm was measured, with 300 s chosen as the 
arbitrarycut-off time. Animals performed three trials 
for each evaluation, and the longest duration achieved 
was recorded. PaGE was used to quantify the grip 
strength of the mouse. The wire lid was gently shaken 
to prompt the mouse to hold onto the grid before the 
lid was flipped upside down. The time before the 
mouse let go of the grid with at least both hindlimbs 
was measured. Each mouse was allowed three attempts 
to hold onto the inverted lid for an arbitrary maximum Joo IS, et al. Memantine Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
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Figure 1. Effects of memantine treatment on motor performance 
in G93A transgenic mice. Cumulative probability of the onset 
of deficit in rotarod (A), paw grip endurance (PaGE) (B), 
and extension reflex (C) tests. There was a trend toward an 
improved rotarod performance and delayed loss of extension 
reflex, although the effect was not statistically significant. Me-
mantine had no effect on PaGE.
of 200 s, and the longest duration was recorded. The 
extension reflex was quantified using the following 
4-point scoring system: 0 for loss of reflex, with 
hindlimbs and paws held close to the body; 1 for 
loss of reflex with marked flexion of the hindlimbs; 
2 for hindlimbs extending to <90 degrees with a 
decreased extension reflex in bilateral hindlimbs; 3 
for hindlimbs extending to <90 degrees with decreased 
extension reflex in unilateral hindlimbs; and 4 for 
hindlimbs reflexly extending to form an angle of 
approximately 120 degrees. The body weight of the 
mice was measured twice weekly.
The day of death was defined as when a mouse 
could no longer roll over within 30 s after being 
placed on its side on a flat surface.
3. Statistical analysis
All statistical analyses were performed using SPSS 
12.0 for Windows software. Analysis of variance 
was used to analyze the significance of differences in 
behavioral performance and body weight. The Kaplan- 
Meier method was used to assess survival data. 
Statistical significance was accepted at the p<0.05 
level.
RESULTS
The onset of disease in G93A transgenic mice was 
defined as the first day on which hindlimb weakness 
appeared, including tremor or altered splay reflex. 
( A )                   Rotarod ( B )               Extension Reflex
( C )              Paw Grip EnduranceJournal of Clinical Neurology: Vol. 3, No. 4, 2007
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Figure 2. Cumulative probabilities for survival in animals 
treated with low-dose memantine (30 mg/kg/day), high-dose 
memantine (90 mg/kg/day), or water alone, starting at 
symptom onset at 75 days of age. Mortality was significantly 
delayed in G93A transgenic mice receiving low-dose me-
mantine (p<0.05).
Memantine was administered orally at the end of 11 
weeks of age (75 days of age) when the mice showed 
the initial clinical signs.
Low- and high-dose memantine treatments tended 
to delay disease progression as assessed by be-
havioral performances, but the protective effect of 
memantine was not statistically significant compared 
with control (values in the control, low-dose memantine, 
and high-dose memantine groups: 112, 116, and 119 
days on the rotarod, and 91, 102, and 112 days on 
the extension reflex, respectively) (Fig. 1). In addition, 
no statistically significant difference was observed 
between the two memantine-treated groups, although 
further motor deterioration in the rotarod test and 
extension reflex tended to be delayed in the high- 
dose memantine group relative to the low-dose me-
mantine group. Memantine treatment did not show 
any protective effect on the body weight or PaGE. 
However, low-dose memantine significantly prolonged 
the survival of the animals relative to control and 
high-dose memantine treatment: the median survival 
was 141 days in the low-dose memantine group but 
135.5 and 134 days in the high-dose memantine and 
control groups, respectively (p<0.05, see Fig. 2). 
No significant adverse effects associated with me-
mantine treatment were observed. 
DISCUSSION
NMDA-receptor-mediated neurotoxicity has been 
implicated in a broad spectrum of neurological dis-
orders, including ALS. The current data show that 
memantine (an NMDA receptor antagonist) prolongs 
the survival of G93A transgenic ALS mice by about 
1 week (~5% of the life span). Although we observed 
some tendencies, we found that memantine had no 
significant protective effect on motor deterioration. 
These results are similar to the effects of riluzole 
found in two human clinical trials,
7,8 as well as in an 
animal study.
20 Riluzole exhibits a variety of phar-
macologic actions, including inhibition of glutamate 
release from presynaptic nerve terminals,
21 modulation 
of both NMDA
22 and AMPA receptors,
23 and inhibition 
of high-affinity uptake of γ-aminobutyric acid.
24 Such 
diverse and nonspecific actions of riluzole would in-
evitably cause a variety of intolerable adverse effects. 
For this reason, an antiexcitotoxic therapy should act 
specifically and must block excessive activation of 
the relevant receptors, leaving normal function relatively 
intact in order to avoid side effects.
Memantine is a specific, noncompetitive open- 
channel NMDA receptor blocker with a rapid off- 
rate from the channel, permitting the preferential 
blockade of excessive NMDA receptor activity 
without disrupting normal activity.
12,13 Many neuro-
degenerative diseases – including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, and ALS 
– have a final common pathway of neuronal injury 
as a result of glutamate receptor overstimulation, 
especially of the NMDA subtype.
25 Therefore, me-
mantine might be a good candidate treatment for 
alleviating excitotoxicity associated with several neuro-
degenerative diseases. In fact, memantine has been 
used clinically for over 20 years to treat Parkinson’s 
disease, vascular dementia, and Alzheimer’s disease. 
Moreover, the long-term safety and efficacy of 
memantine has been confirmed in the treatment of 
patients with moderate-to-severe Alzheimer disease.
26Joo IS, et al. Memantine Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
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Many in vitro and in vivo studies have demonstrated 
the antiexcitotoxic effects of memantine in several 
neurodegenerative diseases, but there have been sur-
prisingly few attempts to determine its effects on 
ALS. To our knowledge only one recent study
18 has 
investigated this, and concluded that the neuro-
protective effect of memantine in a transgenic ALS 
mouse model carrying a high copy number of SOD1 
(G93A) was probably due to the inhibition of spinal 
cord NMDA receptors, and suggested that meman-
tine could be used in ALS patients to prolong survival. 
Despite these promising results, that study had limi-
tations: (1) the memantine treatment began before 
the onset of symptoms due to there being no reliable 
diagnostic biomarkers for human ALS,
27 and (2) the 
delivery method was a subcutaneous injection, which 
is not readily applicable to patients with ALS.
In the present study, we demonstrated that the 
administration of memantine even at symptom onset 
(75 days of age) had therapeutic effects in ALS. 
Although the earliest deficits in motor power and 
coordination in SOD1 (G93A) transgenic mice are 
observed as early as 8 weeks of age, the designated 
onset time may differ with the test used for motor 
assessment.
28  The first clinical signs in the mice used 
in this study appeared at about 11 weeks of age, 
with the mice showing tremor, impairment of the 
hindlimb extension reflex, and reduced running time 
on the rotarod apparatus. While memantine significantly 
prolonged survival, no significant beneficial effects 
on motor performance, hindlimb extension reflex, or 
weight were detected. Such partial effects might be 
attributable to the delay in memantine treatment, or 
to motor neuron degeneration in ALS mice not being 
mediated via activation of NMDA receptors alone, 
since there is evidence that AMPA/kainate receptors 
play a major role in neurotoxicity.
29 In this regard, 
a previous experimental study has demonstrated that 
an AMPA/kainate receptor antagonist significantly 
protected against the calcium influx and neurotoxicity, 
while an NMDA receptor antagonist had only a mild 
effect.
30 Moreover, Tortarolo et al. demonstrated that 
a new noncompetitive AMPA antagonist partially 
protected motor neurons, improved motor function, 
and prolonged the survival of SOD1 (G93A) transgenic 
ALS mice.
31
Memantine exerted a dose-dependent protective 
effect on motor deterioration but not on survival. This 
discrepancy might be due to erratic ingestion of the 
water containing memantine. We did not estimate the 
plasma concentration of memantine. The therapeutic 
plasma concentration of memantine for Alzheimer’s 
disease is approximately 1 μM.
32 The steady-state 
plasma levels following oral administration of 10, 
30, and 100 mg/kg/day memantine were reportedly 
0.49±0.06, 1.14±0.07, and 5.54±0.4 μM (mean±SD), 
respectively, in male C56BL/6J mice.
33 Based on 
these data, a dose of 30 mg/kg/day should produce 
the therapeutic plasma level of 1 μM in Alzheimer’s 
disease. Additional work is needed to explore whether 
a serum level of 1 μM is also effective in ALS.
In conclusion, we have confirmed that memantine 
prolongs the survival of and delays motor deterio-
ration in SOD1 (G93A) transgenic ALS mice. These 
results combined with those from a previous memantine 
study for ALS
18 suggest that memantine could be 
used as a new and effective NMDA receptor anta-
gonist to manage human ALS patients with acceptable 
long-term safety and tolerability. The next steps are 
to determine whether memantine is also effective in 
human ALS and whether a combination therapy with 
other agents exerts better therapeutic effects than 
memantine treatment alone.
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